YOLFTbeta
Entrada Therapeutics Inc

Entrada Therapeutics Inc

TRDA · NASDAQ · Healthcare / Biotechnology

5.09USD-0.08 (-1.55%)

Price History

Full chart

Market Stats

Previous Close5.17
Open5.17
Day Range4.91 – 5.25
52-Week Range5.55 – 16.45
Volume791.63K
Market Cap239.85M
P/E (TTM)0.00
Forward P/E3333.33
EPS-3.96
Dividend Yield0.00%
Beta-0.25
50-Day Avg6.93
200-Day Avg9.48

About

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dipal Doshi
  • Employees152
  • HeadquartersOne Design Center Place, Boston, MA, United States, 02210, USA
  • Websitehttps://www.entradatx.com

Leadership

  • Mr. Dipal DoshiCEO & Director · b. 1976
  • Mr. Nathan J. DowdenPresident & COO · b. 1971
  • Dr. Natarajan Sethuraman Ph.D.President of Research & Development · b. 1962
  • Mr. Kory James Wentworth CPACFO & Treasurer · b. 1979
  • Dr. Jared Cohen J.D., Ph.D.General Counsel
  • Ms. Karla MacDonaldChief Corporate Affairs Officer
  • Mr. Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs
  • Sandeep BasnetHead of Information Technology

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00025.26M129.01M210.78M25.42M
Growth (%)----+410.74%+63.38%-87.94%
Cost of Revenue104.00K326.00K1.12M1.90M99.88M3.77M4.10M
Gross Profit-104.00K-326.00K-1.12M-1.90M129.01M210.78M21.32M
Gross Margin----7.50%100.00%100.00%83.89%
Operating Expense11.72M26.34M50.01M95.35M132.18M163.77M177.32M
Operating Income-11.82M-26.67M-51.13M-97.25M-3.16M47.01M-156.00M
Operating Margin----384.99%-2.45%22.30%-613.66%
EBITDA-11.72M-26.20M-50.01M-95.35M14.90M70.26M-142.40M
EBITDA Margin----377.49%11.55%33.33%-560.17%
Net Income-4.65M-26.52M-50.07M-87.46M-6.68M65.63M-143.75M
Net Income Margin----346.23%-5.18%31.13%-565.48%
R&D8.22M21.10M35.93M66.61M99.88M125.31M142.27M
R&D as % of Total Revenue---263.69%77.42%59.45%559.65%
Interest Expense0031.00K2.63M---
Interest Expense % of Total Revenue---10.42%---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets18.24M43.53M305.83M252.06M469.19M526.32M377.38M
Total Liabilities33.76M85.02M7.12M39.50M226.83M97.64M71.25M
Total Equity-15.52M-41.49M298.72M212.55M242.36M428.68M306.13M
Cash16.84M39.05M291.06M45.16M67.60M101.21M90.39M
Total Debt---25.94M68.23M59.21M50.93M
Net Debt-16.84M-39.05M-291.06M-19.22M628.00K-42.00M-39.46M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.80M-25.57M-50.86M-93.79M139.80M-41.56M-128.51M
Investing Cash Flow-630.00K-2.32M-4.58M-148.65M-138.40M-27.80M116.81M
Financing Cash Flow38.00K50.09M307.46M479.00K21.04M102.96M887.00K
Capital Expenditure630.00K2.32M4.58M2.89M5.61M3.16M1.04M
Free Cash Flow-11.43M-27.89M-55.44M-96.67M134.19M-44.72M-129.55M
FCF to OCF105.83%109.07%109.00%103.08%95.98%107.60%100.81%

Earnings

Report DateMar 31, 2020Jun 30, 2020Mar 31, 2021Jun 30, 2021Sep 1, 2021Dec 9, 2021Mar 15, 2022May 12, 2022Aug 11, 2022Nov 7, 2022Mar 6, 2023May 10, 2023Aug 8, 2023Nov 7, 2023Mar 13, 2024May 7, 2024Aug 13, 2024Nov 5, 2024Mar 3, 2025May 8, 2025Aug 6, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 5, 2026Nov 5, 2026
EPS Estimate0.000.000.000.000.00-0.91-1.28-0.65-0.73-0.77-0.83-0.84-0.60-0.63-0.17-0.470.33-0.62-0.67-0.77-0.86-0.96-1.32-1.02-1.16-0.98
EPS Actual-5.18-5.18-7.08-7.08-0.45-9.78-0.89-0.69-0.74-0.80-0.79-0.21-0.781.02-0.290.681.55-0.350.03-0.42-1.04-1.06-0.94-0.95-1.01-
Surprise------974.73%30.47%-6.15%-1.37%-3.90%4.82%75.00%-30.00%261.90%-70.59%244.68%369.70%43.55%104.48%45.45%-20.93%-10.42%28.79%6.86%12.93%-
Timing-----After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap239.85M
Enterprise Value78.63M
Trailing P/E0.00
Forward P/E3333.33
Price / Sales51.18
Price / Book1.12
EPS-3.96
Book Value6.47
Revenue (TTM)4.69M
Gross Profit (TTM)-134.36M
EBITDA-170.86M
Profit Margin0.00%
Operating Margin-5007.02%
Return on Equity-54.10%
Return on Assets-29.20%
Shares Outstanding38.94M
Shares Float20.10M
Beta-0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 19.00
  • Strong Buy
    2
  • Buy
    2

Ownership Breakdown

Institutions
82.11%
Insiders
12.23%
Retail / Other
5.66%

Top Institutional Holders

  • Baker Bros Advisors LP
    5.07M13.03%
  • 5AM Venture Management, LLC
    4.06M10.42%
  • BlackRock Inc
    2.36M6.06%
  • Merck & Co Inc
    1.74M4.47%
  • Vanguard Capital Management, LLC
    1.26M3.23%
  • MPM Oncology Impact Management LP
    1.25M3.22%
  • TCG Crossover Management, LLC
    1.06M2.72%
  • Wellington Management Company LLP
    954.42K2.45%
  • Millennium Management LLC
    763.96K1.96%
  • StepStone Group LLC
    761.28K1.96%
  • Geode Capital Management, LLC
    667.35K1.71%
  • State Street Corp
    533.80K1.37%
  • T. Rowe Price Associates, Inc.
    526.04K1.35%
  • Citadel Advisors Llc
    394.32K1.01%
  • Dimensional Fund Advisors, Inc.
    376.14K0.97%
  • Jacobs Levy Equity Management, Inc.
    333.91K0.86%
  • Acadian Asset Management LLC
    333.17K0.86%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    953.73K2.45%
  • iShares Russell 2000 ETF
    756.49K1.94%
  • MEDICAL BioHealth EUR Acc
    454.61K1.17%